{"name":"Xspray Pharma AB","slug":"xspray-pharma-ab","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"XS003 under fed and fasted condition","genericName":"XS003 under fed and fasted condition","slug":"xs003-under-fed-and-fasted-condition","indication":"Other","status":"phase_1"},{"name":"XS005 Sorafenib Capsule A - Period 1","genericName":"XS005 Sorafenib Capsule A - Period 1","slug":"xs005-sorafenib-capsule-a-period-1","indication":"Other","status":"phase_1"},{"name":"XS005 Sorafenib Capsule A - Period 2","genericName":"XS005 Sorafenib Capsule A - Period 2","slug":"xs005-sorafenib-capsule-a-period-2","indication":"Other","status":"phase_1"},{"name":"Dasatinib ASD","genericName":"Dasatinib ASD","slug":"dasatinib-asd","indication":"Other","status":"phase_1"},{"name":"Sorafenib - Period 1","genericName":"Sorafenib - Period 1","slug":"sorafenib-period-1","indication":"Other","status":"phase_1"},{"name":"Sorafenib - Period 3","genericName":"Sorafenib - Period 3","slug":"sorafenib-period-3","indication":"Other","status":"phase_1"},{"name":"XS005 Sorafenib Tablet A - Period 3","genericName":"XS005 Sorafenib Tablet A - Period 3","slug":"xs005-sorafenib-tablet-a-period-3","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"XS003 under fed and fasted condition","genericName":"XS003 under fed and fasted condition","slug":"xs003-under-fed-and-fasted-condition","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"XS005 Sorafenib Capsule A - Period 1","genericName":"XS005 Sorafenib Capsule A - Period 1","slug":"xs005-sorafenib-capsule-a-period-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"XS005 Sorafenib Capsule A - Period 2","genericName":"XS005 Sorafenib Capsule A - Period 2","slug":"xs005-sorafenib-capsule-a-period-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dasatinib ASD","genericName":"Dasatinib ASD","slug":"dasatinib-asd","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sorafenib - Period 1","genericName":"Sorafenib - Period 1","slug":"sorafenib-period-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sorafenib - Period 3","genericName":"Sorafenib - Period 3","slug":"sorafenib-period-3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"XS005 Sorafenib Tablet A - Period 3","genericName":"XS005 Sorafenib Tablet A - Period 3","slug":"xs005-sorafenib-tablet-a-period-3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxONmpQUldWQXg4YTdlaFJxZ1ZKSHVqbEktejVHVC1kWVMwS3lFSjVzdG5DR3ZyTTYyYWQtWUxRYlhzWGhSZFZQTDY0VkRsdW54eFd2RjU2R210aFFrdXRsaFBna01ZWkpXajZ3QlZtaUZTYTdZYmhDSDAwTnd3SjVvLUZvWGQ?oc=5","date":"2026-04-05","type":"pipeline","source":"marketscreener.com","summary":"Xspray Pharma AB: Shareholders Board Members Managers and Company Profile | SE0028355099 - marketscreener.com","headline":"Xspray Pharma AB: Shareholders Board Members Managers and Company Profile | SE0028355099","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPMjhrUDNUU3NKdGotSkY0Sk9BeG9IdDFVOW9sSlBpZlM4Z2liVEllWVN4T2tzWElHakQyU3VFeF96SEJXaU9OeWtsWkRPRVR3dFRDd1ktN1IzcjJZRElRcExkV1ZYT0lhb0Jsdld0ZTM3THBWblIyOVp5eXROWEdXVmJlTWMtUQ?oc=5","date":"2026-04-05","type":"trial","source":"marketscreener.com","summary":"Xspray Pharma AB: Financial Data Forecasts Estimates and Expectations | XSPRAY BTA | SE0028355099 - marketscreener.com","headline":"Xspray Pharma AB: Financial Data Forecasts Estimates and Expectations | XSPRAY BTA | SE0028355099","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPNnR5a2FKNVVQbXNBV2JvRFRmWEZDaFZWZjhJY2h0ZVZfZjdhX19fVzdPSkl3SENDN3ZpNHFhUlV2WkxUMmhNZXFBdGxubzJMMktjVjFJRVQ3VUkxeXRGZncyekcwb3k3a3h1OWQtbW11VlpRN1dRZ2F6aUlBZUVHcXgzVlJGSFhwbms3Zm8xMXM3Q1plZ1dvczlUaUZodk5Nb3B0LWJsaDRsalVLT1Myd09ObERLTVhTcHcwRXhR?oc=5","date":"2026-03-31","type":"pipeline","source":"TipRanks","summary":"Xspray Pharma launches SEK 83m rights issue to fund oncology pipeline - TipRanks","headline":"Xspray Pharma launches SEK 83m rights issue to fund oncology pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQSnNxSW1jQ3VBWlRzT1NVcDNZcENSdGZqOWVyekZCekYwUlVjWXg0bWRqbGpjdS1Cdk0yVHFrd2RJTkVLblZEY2pDVjlhYWNKQk0tWVRORFhBSjdYNy1tMEptRE50LVJKaEh3QmJsdWhCd2Q4RXVUQXB1REJ0MzR1R2NnMTRDVjJKU0RlQVlqM20xV3N5bGo5OFpYNTNxcFp0WjNOeE5Iek9WLU9iQ3J3cjcwMjl0Um5fRV8xVmd6TQ?oc=5","date":"2026-03-26","type":"pipeline","source":"TipRanks","summary":"Xspray Pharma’s Rights Issue Oversubscribed and Over-Allotment Expanded - TipRanks","headline":"Xspray Pharma’s Rights Issue Oversubscribed and Over-Allotment Expanded","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNaVM0bVZCb0lYLXVRTnh4Yk1jRmZfTVNlcFp6U1pRc0lSWjJwcTZ4S04tUTlWbDkyRk11N19ucmdodXMyOWNIdDhOSjFIZnJ3RmtOaFFsX3AwazRhbjJQa3NGbkRKb2tSVVp5QXBnRlFUdjgxUTh6UjNqOVhxcm5oTjEwVkZYOVBaUTg4Y004S045ZnFuNFd4a0tmbU1qZG1iV0NuVUdiamhaVGUyTnpGQkIteTRiRkhMbjFKWA?oc=5","date":"2026-03-25","type":"pipeline","source":"marketscreener.com","summary":"Xspray Pharma surges as CEO declares drug launches closer than ever - marketscreener.com","headline":"Xspray Pharma surges as CEO declares drug launches closer than ever","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOZnJLeUpfOE9vS2NMRmJpcUZMNDhLVDM2TXRlbU01MnVtaGVtMkNhRUctUjFiakRsN2U4ZTVEamJObFBjempnTkU4YW1ZSDJUbHJvOFhwSEh3b1JRNi14YTFna25WQXhqS2RxamhaeElMbXEyTEktV1VpNjc4cm8tQmRJUVhESGc3YVB3enlHcnVxSnRTOVlWMm9HdFRyVUtHOEtPZ1k5cGdUOC1ZNEktaGNyeTlyemgwRFBFOXNfZF81T2doSHQwQzVHSTRxUQ?oc=5","date":"2026-03-24","type":"pipeline","source":"TipRanks","summary":"Xspray Pharma Launches SEK 83 Million Rights Issue to Fund Oncology Drug Launches - TipRanks","headline":"Xspray Pharma Launches SEK 83 Million Rights Issue to Fund Oncology Drug Launches","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNQjBqTHd3RmpiVUJRc1ByNmUtX2taSUtDcWYyZXR6bWhpVmxsX2FQZmJqMmVKSG5MWWpFdkVoNEwzY2IxdUF0RmZhRE9lSFpGQ1NDNnRkdkVENERoVFVibHE3WlNuYVdudUN6aTZKVlRpUjdtNUNjOG9pSnBuQ2FJTWMyeXNlVVVWUVpTWWFMamxweTJRSExiblFSa2dlSVFyUUhVTkV4QzhsWGlKSmlrRFktOVNyaXJCREdFQ1Q0T2JkbW9KR2p0eGNSZXE?oc=5","date":"2026-03-11","type":"regulatory","source":"TipRanks","summary":"Xspray Pharma Wins FDA Review Slot for Dasynoc Ahead of Planned 2026 Dual Launch - TipRanks","headline":"Xspray Pharma Wins FDA Review Slot for Dasynoc Ahead of Planned 2026 Dual Launch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxPSGY3UUg5N2p4b1gzZEhfZnNMSVl6NmRvb0NSanU4NkZBblRVb3BHNHRXVFpYMFhsOEpvNVU4Vl9NMk9NZ2c2Rk9ZOEZCSXlnWVFlUnFyV0VkSG5UUmIwanplRzctaG5GN3RzUF9VVkVCVERFTDdINU1DSnJVQWl6MkZ1VUVBZFJzVUpzakgtR2hORFBWM1dqVGZaOTdUR3ZVbXRqVnFXUGQwbDNZdzlxdDByRVROMXFvRkd1U2hNeTcweXpRZndrcFFvcU1ucXdielhYeG1OQnJVd1pfZjJRcEVtdWZVVFczdFlMdk9IelNKMVlPWG1VUTJYOW9QSXhCXzdKVXlvbmVWcXhWOFVMd3EzNjByM2NscWhaTnEzLVJMNldvTGVSbkpaMA?oc=5","date":"2026-02-27","type":"regulatory","source":"TradingView","summary":"Flerie’s portfolio company Xspray Pharma appoints Blake Leitch as CEO and resubmits application for market approval of Dasynoc® to the FDA - TradingView","headline":"Flerie’s portfolio company Xspray Pharma appoints Blake Leitch as CEO and resubmits application for market approval of D","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNMURucW1lSjVmcVRqenNoNUZ6YklGd0FPUHd4WF8xRXExWk5mSjVZeWVZeUtkdVAyNGZwNkdSajE5aFAwSy1iMjdtdlJicnh5Qks5ZlJMT0M4a2w0aE1UWFR1X2lvMnVKTkFzVUkya3FjREljbjdvYnk4SUtzdWR1amZNOEpiVTBiVHJfRG9lU2sxWmZXTFdSVGhHWU5vRVZCb1ZGa0lHanhZTnREOTYwa2xLQm1neWFIS3dPUEx5RWF4YWxreERKbV9uY1FGaXNzVUJITUhmcEl4WGhabUstQXBvZlRKaFVYb3h5dVNn?oc=5","date":"2025-08-19","type":"regulatory","source":"Business Wire","summary":"Xspray Pharma Submits XS003 to the FDA – The Company’s Second Product Candidate from the HyNap Platform - Business Wire","headline":"Xspray Pharma Submits XS003 to the FDA – The Company’s Second Product Candidate from the HyNap Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQOFMyOWpPei1ld1pSaDJLVHowMVJmLWU0OFRjQ0wzb2Z5bENpQUJSOHc2dXhLdktOenU5VWxLa055dTdnZU5nLUVpTXp5RkxOcEpSektpZk5LOW91WVVaSEZRUW4yLUk5aDBYdnRHRTU3UWppRXRJVWcwTjQ4QXRtWjR5SlhJbUJHOHFR?oc=5","date":"2025-08-12","type":"deal","source":"Yahoo Finance","summary":"Xspray Pharma Signs License Agreement with Handa Therapeutics – to Receive up to Double-Digit Royalty on Handa’s Net Proceeds - Yahoo Finance","headline":"Xspray Pharma Signs License Agreement with Handa Therapeutics – to Receive up to Double-Digit Royalty on Handa’s Net Pro","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPeE9yaHdydnlTb29nTV84QTdEdWtpT0ZNU0FaeURGeFFxaExCbFJmcHljQk9VOHBiMGdhU0s5VUE1dU92VGJqQ3ZhM2d0clNMSnNHY1hWRmZNMkRYUHlYN2RkVkJOanRRRUdvbTZ6OVQzZUdWTXl6NVJZbUgwVF9LZmVnUjJGQy1scnJzaU8tNnhROEF6Mjlfa0h2X0ZhaUZ5V20wbnRlTjBveGdDMmpvb3IxdmVHclk0TzEyeWdvNGJBa1BUR3B1UHBDR2NUaDN2bWdScUhIVTRZS1ZlcWtrNWp2dnFiRU1aajdoRktJMkpCY1lxZlhscWgtSXRueFNCRk04dFlmYzg2blU?oc=5","date":"2025-08-12","type":"deal","source":"Business Wire","summary":"Xspray Pharma Signs License Agreement with Handa Therapeutics – to Receive up to Double-Digit Royalty on Handa’s Net Proceeds - Business Wire","headline":"Xspray Pharma Signs License Agreement with Handa Therapeutics – to Receive up to Double-Digit Royalty on Handa’s Net Pro","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE8tUjBTdVd3WWx2SnhNVU9GRW9vMGVwXzc3RjRncDg0MGpYQkt0OEVQVnlLNlRKWTlkc1RNenZSbmZkUjh2QTBvSE5BbUdGcVhPZXE1VnJRR1JncVNkUG53?oc=5","date":"2018-04-14","type":"pipeline","source":"TradingView","summary":"XSPRAY Stock Price and Chart — OMXSTO:XSPRAY - TradingView","headline":"XSPRAY Stock Price and Chart — OMXSTO:XSPRAY","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_1":7},"enrichmentLevel":0,"visitCount":13,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}